| __timestamp | Alnylam Pharmaceuticals, Inc. | Amneal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 106735000 |
| Thursday, January 1, 2015 | 276495000 | 136870000 |
| Friday, January 1, 2016 | 382392000 | 204747000 |
| Sunday, January 1, 2017 | 390635000 | 191938000 |
| Monday, January 1, 2018 | 505420000 | 210451000 |
| Tuesday, January 1, 2019 | 655114000 | 202287000 |
| Wednesday, January 1, 2020 | 654819000 | 190585000 |
| Friday, January 1, 2021 | 792156000 | 209563000 |
| Saturday, January 1, 2022 | 883015000 | 200046000 |
| Sunday, January 1, 2023 | 1004415000 | 167778000 |
| Monday, January 1, 2024 | 1126232000 |
Unleashing the power of data
In the competitive world of pharmaceuticals, research and development (R&D) spending is a key indicator of innovation and future growth. Alnylam Pharmaceuticals, Inc. and Amneal Pharmaceuticals, Inc. have been on divergent paths in this regard over the past decade. Since 2014, Alnylam has consistently outpaced Amneal in R&D investment, with a staggering 428% increase by 2023. In contrast, Amneal's R&D spending has remained relatively stable, peaking in 2018 and then experiencing a slight decline.
Alnylam's commitment to innovation is evident, with its R&D expenses reaching over $1 billion in 2023, a significant leap from $190 million in 2014. This strategic focus on R&D underscores Alnylam's ambition to lead in the biotech sector. Meanwhile, Amneal's more conservative approach, with R&D expenses hovering around $200 million annually, reflects a different business strategy, possibly focusing on cost efficiency and market consolidation.
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and United Therapeutics Corporation
R&D Insights: How Alnylam Pharmaceuticals, Inc. and Intra-Cellular Therapies, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Incyte Corporation
Research and Development: Comparing Key Metrics for Alnylam Pharmaceuticals, Inc. and Exelixis, Inc.
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Opthea Limited
Alnylam Pharmaceuticals, Inc. and Amneal Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Xencor, Inc.
Research and Development Investment: Halozyme Therapeutics, Inc. vs Amneal Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. vs Amneal Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Amneal Pharmaceuticals, Inc. vs Rhythm Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Amneal Pharmaceuticals, Inc. vs CRISPR Therapeutics AG: Strategic Focus on R&D Spending